Tailored Therapy for Clarithromycin-Resistant H. Pylori

Kangdong Sacred Heart Hospital782 enrolled

Overview

Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

782

Conditions

Helicobacter Pylori Infection

Interventions

PAMDRUG

treatment with PPI, metonidazole, amoxicillin

PBMTDRUG

treatment with PPI, metonidazole, bismuth, tetracyclin

Eligibility

Sex: ALLMin age: 19 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * peptic ulcer disease * H. pylori gastritis * low grade MALT lymphoma Exclusion Criteria: * history of gastric cancer surgery * severe comorbidity (ESRD, LC) * hypersensitivity to drug * pregnancy

Locations (1)

Kangdong Sacred Heart Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

H. pylori eradication rate

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.